Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

NCT01116219 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT01116219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01116219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
May 31, 2016
Enrollment
149 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer